XLRN News and Press, Acceleron Pharma Inc. From 05/09/19

– Luspatercept Biologics License Application (BLA) and Marketing Authorization Application (MAA) submitted in April 2019 – – Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Char...

Acceleron Pharma (NASDAQ: XLRN ) is scheduled to announce Q1 earnings results on Thursday, May 9th, after market close. The consensus EPS Estimate is -$0.57 (+1.7% Y/Y) and the consensus Revenue Estimate is $3.67M (+13.6% Y/Y). Over the last 1 year, xlrn has beaten EPS estimates 50% ...

AAXN , AGO , AIRG , AL , ALRM , ALTR , AMBC , AMBR , AMPH , AQN , ASYS , BGNE , BKNG , CABO , CARG , CISN , CORT , CTRL , CUTR , DBX , EFX , ELY , EQH , FGEN , FLY , FSCT , GH , GLOB , GPRO , GSBD , ICUI , JAG , MAIN , MAXR , MTD , MTW , NDLS , NTR , N...

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned ...

Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up  1%  premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/M...

Celgene (NASDAQ: CELG ) has submitted a marketing application Europe seeking approval for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions an...

Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medici...

Genfit (NASDAQ: GNFT ) initiated with Overweight rating and $55 (120% upside) price target at Barclays. More news on: Genfit SA, Acceleron Pharma Inc., Retrophin, Inc., Healthcare stocks news, Read more ...

Celgene ( CELG ) and its partner Acceleron Pharma ( XLRN ) announced that they had submitted their BLA for their biologic luspatercept to the FDA for potential regulatory approval. The BLA to the FDA will be for two different diseases associated with anemia. In addition, a regulatory submiss...